Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|1|10-19

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.1, 2018-01, pp. : 10-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 314-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E86-E91

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 247-254

Karger

Access to resources Recommend Favorite

RAS mutation status and bortezomib therapy for relapsed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 905-908

John Wiley & Sons Inc

Access to resources Recommend Favorite